Literature DB >> 21273302

Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening.

Lucinda Brown1, Jinhua Xu-Bayford, Zoe Allwood, Mary Slatter, Andrew Cant, E Graham Davies, Paul Veys, Andrew R Gennery, H Bobby Gaspar.   

Abstract

Severe combined immunodeficiency (SCID) carries a poor prognosis without definitive treatment by hematopoietic stem cell transplantation. The outcome for transplantation varies and is dependent on donor status and the condition of the child at the time of transplantation. Diagnosis at birth may allow for better protection of SCID babies from infection and improve transplantation outcome. In this comparative study conducted at the 2 designated SCID transplantation centers in the United Kingdom, we show that SCID babies diagnosed at birth because of a positive family history have a significantly improved outcome compared with the first presenting family member. The overall improved survival of more than 90% is related to a reduced rate of infection and significantly improved transplantation outcome irrespective of donor choice, conditioning regimen used, and underlying genetic diagnosis. Neonatal screening for SCID would significantly improve the outcome in this otherwise potentially devastating condition.

Entities:  

Mesh:

Year:  2011        PMID: 21273302     DOI: 10.1182/blood-2010-08-300384

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  77 in total

1.  Neonatal screening for severe combined immunodeficiency.

Authors:  Jennifer M Puck
Journal:  Curr Opin Pediatr       Date:  2011-12       Impact factor: 2.856

Review 2.  The long quest for neonatal screening for severe combined immunodeficiency.

Authors:  Rebecca H Buckley
Journal:  J Allergy Clin Immunol       Date:  2012-01-24       Impact factor: 10.793

3.  Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles.

Authors:  Jennifer M Puck
Journal:  J Allergy Clin Immunol       Date:  2012-01-29       Impact factor: 10.793

4.  Newborn screening for severe combined immunodeficiency; the Wisconsin experience (2008-2011).

Authors:  James W Verbsky; Mei W Baker; William J Grossman; Mary Hintermeyer; Trivikram Dasu; Benedetta Bonacci; Sreelatha Reddy; David Margolis; James Casper; Miranda Gries; Ken Desantes; Gary L Hoffman; Charles D Brokopp; Christine M Seroogy; John M Routes
Journal:  J Clin Immunol       Date:  2011-11-10       Impact factor: 8.317

Review 5.  Flow Cytometry, a Versatile Tool for Diagnosis and Monitoring of Primary Immunodeficiencies.

Authors:  Roshini S Abraham; Geraldine Aubert
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

Review 6.  History and current status of newborn screening for severe combined immunodeficiency.

Authors:  Antonia Kwan; Jennifer M Puck
Journal:  Semin Perinatol       Date:  2015-04-30       Impact factor: 3.300

7.  A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID).

Authors:  Kee Chan; Joie Davis; Sung-Yun Pai; Francisco A Bonilla; Jennifer M Puck; Michael Apkon
Journal:  Mol Genet Metab       Date:  2011-07-12       Impact factor: 4.797

8.  Fiscal implications of newborn screening in the diagnosis of severe combined immunodeficiency.

Authors:  Catherine Kubiak; Soma Jyonouchi; Caroline Kuo; Maria Garcia-Lloret; Morna J Dorsey; John Sleasman; Arthur S Zbrozek; Elena E Perez
Journal:  J Allergy Clin Immunol Pract       Date:  2014-08-28

9.  The United Kingdom Primary Immune Deficiency (UKPID) registry 2012 to 2017.

Authors:  B Shillitoe; C Bangs; D Guzman; A R Gennery; H J Longhurst; M Slatter; D M Edgar; M Thomas; A Worth; A Huissoon; P D Arkwright; S Jolles; H Bourne; H Alachkar; S Savic; D S Kumararatne; S Patel; H Baxendale; S Noorani; P F K Yong; C Waruiru; V Pavaladurai; P Kelleher; R Herriot; J Bernatonienne; M Bhole; C Steele; G Hayman; A Richter; M Gompels; C Chopra; T Garcez; M Buckland
Journal:  Clin Exp Immunol       Date:  2018-06       Impact factor: 4.330

Review 10.  Immune Gamma Globulin Therapeutic Indications in Immune Deficiency and Autoimmunity.

Authors:  Luanna Yang; Eveline Y Wu; Teresa K Tarrant
Journal:  Curr Allergy Asthma Rep       Date:  2016-07       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.